681807-60-3 Usage
Uses
Used in Pharmaceutical Research:
Cyclopropanecarboxylic acid, 1-amino-2-ethenyl-, ethyl ester, hydrochloride (9CI) is utilized as a key intermediate in the synthesis of pharmaceutical compounds for various therapeutic purposes. Its unique structure allows for the development of molecules with specific biological activities, contributing to the advancement of medicinal chemistry.
Used in Organic Synthesis:
In the field of organic synthesis, Cyclopropanecarboxylic acid, 1-amino-2-ethenyl-, ethyl ester, hydrochloride (9CI) is employed as a building block for creating complex organic molecules. Its cyclopropane ring and functional groups provide a foundation for further chemical reactions, enabling the synthesis of a wide range of organic compounds with diverse applications.
Used in Drug Development:
Cyclopropanecarboxylic acid, 1-amino-2-ethenyl-, ethyl ester, hydrochloride (9CI) is used as a precursor in the development of new drugs. Its structural features can be modified to create novel pharmaceutical agents with improved efficacy, selectivity, and safety profiles, thus playing a crucial role in the discovery of innovative therapeutics.
Used in Chemical Research:
Cyclopropanecarboxylic acid, 1-amino-2-ethenyl-, ethyl ester, hydrochloride (9CI) is also valuable in chemical research, where it can be studied to understand the reactivity and properties of cyclopropane rings and their derivatives. It can be used to explore new reaction pathways and mechanisms, contributing to the broader understanding of organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 681807-60-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,8,1,8,0 and 7 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 681807-60:
(8*6)+(7*8)+(6*1)+(5*8)+(4*0)+(3*7)+(2*6)+(1*0)=183
183 % 10 = 3
So 681807-60-3 is a valid CAS Registry Number.
InChI:InChI=1/C8H13NO2.ClH/c1-3-6-5-8(6,9)7(10)11-4-2;/h3,6H,1,4-5,9H2,2H3;1H
681807-60-3Relevant academic research and scientific papers
CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF
-
Paragraph 00519, (2017/09/27)
The present technology relates to compounds, kits, compositions, and methods useful for the treatment of fibrotic disease. In some aspects, the present technology provides for treatment of various diseases or disorders associated or mediated, at least in part, by calpains, such as CAPN1, CAPN2, and/or CAPN9. The present technology is generally applicable to compounds which inhibit myofibroblast differentiation.
Hepatitis C Virus Inhibitors
-
Page/Page column, (2013/05/21)
Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
Inhibitors of Hepatitis C Virus
-
Page/Page column 20, (2008/12/04)
Macrocyclic peptides are disclosed having the general formula: wherein R3, R3′, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
Hepatitis C Virus Inhibitors
-
Page/Page column 21, (2008/06/13)
Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
Hepatitis C virus inhibitors
-
Page/Page column 35-36, (2008/06/13)
The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the function of the NS3 protease (also referred to herein as “serine protease”) encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS3 protease.
Hepatitis C virus inhibitors
-
Page/Page column 26-27, (2010/02/12)
Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.